Stephen Willey Analyst PerformanceManaging Director at Stifel NicolausStephen Willey is a stock analyst at Stifel Nicolaus in the healthcare sector, covering 27 publicly traded companies. Over the past year, Stephen Willey has issued 35 stock ratings, including buy and hold recommendations. While full access to Stephen Willey's proprietary MarketBeat Analyst Ranking is reserved for MarketBeat All Access subscribers, the rating is updated daily to reflect the most recent analyst activity. This profile highlights Stephen Willey's coverage history, rating activity, and performance tendencies - helping individual investors make more informed trading decisions. Analyst Rankings, Coverage, and Performance StatisticsAnalyst RankingSubscribe to MarketBeat All Access for the analyst's recommendation accuracy rating MarketBeatAverage Return00.00% 12-Month ROISuccess Rate00.00% Profitable RatingsTotal Ratings69 Last 10 YearsBuy Recommendations74.55% 41 Buy RatingsCompanies Covered27 Unique Companies Ratings Distribution55RatingsDistribution of strong buy, buy, hold, and sell ratings by Stephen Willey.RatingPercentageCount Strong Buy0.0%0 ratings Buy74.5%41 ratings Hold25.5%13 ratings Sell0.0%0 ratingsOut of 55 total stock ratings issued by Stephen Willey at Stifel Nicolaus, the majority (74.5%) have been Buy recommendations, followed by 25.5% Hold.Best & Worst CallsBest Call0000.0%CELCJul 2025Subscribe to MarketBeat All Access to get analyst recommendation ROI.Worst Call000.0%INOApr 2020Subscribe to MarketBeat All Access to get analyst recommendation ROI.Exchange CoverageExchangePercentageCountNASDAQ100.0% of companies on NASDAQ27 companiesStephen Willey, an analyst at Stifel Nicolaus, currently covers 27 companies listed on , with the majority traded on NASDAQ.Coverage FocusSector IconSectorPercentageHealthcare27 companies100.0%Stephen Willey of Stifel Nicolaus specializes in stock coverage within the Healthcare sector.Coverage IndustriesIndustryPercentageBIOTECHNOLOGY25 companies92.6%PHARMACEUTICALS2 companies7.4% About Stephen WilleyStephen Willey joined Stifel in 2010 with the acquisition of Thomas Weisel Partners LLC. Stephen is a Managing Director in the Healthcare sector, covering Biotechnology. Before joining Thomas Weisel Partners, Steven worked in research as a Research Scientist at ImClone Systems and as a Research Associate at Mount Sinai School of Medicine. Stephen received an undergraduate degree from University of New Hampshire, earned an MBA from New York University, and an M.S. from University of Rhode Island. Stephen Willey's Ratings History at Stifel Nicolaus Custom Range 1 Month 3 Months 6 Months Year-to-Date 1 Year 2 Years 3 Years 4 Years 5 Years All Time Timeframe Start Date End Date All Ratings Strong Buy Buy Hold Sell Rating Recommendation ROI is the percentage between the price on the Report Date to the price 12 months after the report date.Available with a MarketBeat All Access Subscription12-Month ROIUpgrade to All Access to use the All ROI Filter Export CompanyReport DateActionReport Date Price12-MonthPrice TargetRating12-MonthPrice & ROIDetailsCELCCelcuity8/14/2026Lower Price Target$86.60$150.00Buy$0.0000.00% ROINKTXNkarta8/14/2026Lower Price Target$2.30$10.00Buy$0.0000.00% ROILYELLyell Immunopharma8/6/2026Initiated Coverage$13.45$36.00Buy$0.0000.00% ROIEXELExelixis8/6/2026Boost Price Target$55.20$51.00Hold$0.0000.00% ROIABCLAbCellera Biologics8/6/2026Boost Price Target$6.22$9.00Buy$0.0000.00% ROIINCYIncyte7/28/2026Set Price Target$129.93$145.00$0.0000.00% ROICADLCandel Therapeutics7/13/2026Initiated Coverage$9.49$22.00Buy$0.0000.00% ROINRIXNurix Therapeutics7/10/2026Boost Price Target$23.97$40.00Buy$0.0000.00% ROIINCYIncyte6/9/2026Set Price Target$102.93$123.00$0.0000.00% ROICMPXCompass Therapeutics6/1/2026Set Price Target$2.25$6.00$0.0000.00% ROI Get the Latest News and Ratings for Your StocksEnter your email address below to receive the latest headlines and analysts' recommendations for your stocks with our free daily email newsletter. EXELExelixis5/6/2026Boost Price Target$47.52$47.00Hold$0.0000.00% ROICELCCelcuity5/4/2026Set Price Target$125.65$150.00$0.0000.00% ROIINCYIncyte4/29/2026Boost Price Target$97.74$123.00Buy$0.0000.00% ROICELCCelcuity3/26/2026Boost Price Target$113.25$125.00Buy$0.0000.00% ROIINSMInsmed3/24/2026Boost Price Target$139.20$208.00Buy$0.0000.00% ROIABEOAbeona Therapeutics3/17/2026Set Price Target$4.76$17.00$0.0000.00% ROIZYMEZymeworks3/3/2026Boost Price Target$24.10$47.00Buy$0.0000.00% ROISNDXSyndax Pharmaceuticals2/27/2026Set Price Target$21.71$45.00$0.0000.00% ROICBIOCrescent Biopharma2/26/2026Set Price Target$12.35$29.00$0.0000.00% ROIACLXArcellx2/23/2026Reiterated Rating$113.75$115.00Hold$0.0000.00% ROIIRONDisc Medicine2/17/2026Lower Price Target$63.10$110.00Buy$0.0000.00% ROIINCYIncyte2/11/2026Boost Price Target$100.05$120.00Buy$0.0000.00% ROIEXELExelixis2/11/2026Boost Price Target$42.36$44.00Hold$0.0000.00% ROINRIXNurix Therapeutics1/29/2026Boost Price Target$18.58$35.00Buy$0.0000.00% ROIINCYIncyte1/5/2026Set Price Target$101.79$119.00$0.0000.00% ROICBIOCrescent Biopharma12/4/2025Set Price Target$12.99$32.00$0.0000.00% ROIJANXJanux Therapeutics12/2/2025Lower Price Target$33.99$38.00Buy$0.0000.00% ROIZYMEZymeworks11/19/2025Boost Price Target$22.99$40.00Buy$0.0000.00% ROICELCCelcuity11/13/2025Boost Price Target$87.09$115.00Buy$0.0000.00% ROINKTXNkarta11/11/2025Lower Price Target$1.99$11.00Buy$0.0000.00% ROIXFORX4 Pharmaceuticals11/5/2025Set Price Target$3.60$7.50$0.0000.00% ROIEXELExelixis11/5/2025Set Price Target$39.82$43.00$0.0000.00% ROIIRONDisc Medicine11/3/2025Initiated Coverage$86.22$125.00Buy$0.0000.00% ROIACLXArcellx10/16/2025Set Price Target$92.37$129.00Buy$0.0000.00% ROIINCYIncyte9/22/2025Boost Price Target$85.39$115.00Buy$0.0000.00% ROIXFORX4 Pharmaceuticals8/29/2025Lower Price Target$4.12$9.00Buy$0.0000.00% ROINKTXNkarta8/14/2025Lower Price Target$2.21$12.00Buy$0.0000.00% ROIINSMInsmed8/14/2025Boost Price Target$125.13$145.00Buy$000.0000.00% ROIABCLAbCellera Biologics8/8/2025Lower Price Target$4.13$7.00Buy$0.0000.00% ROIEXELExelixis7/29/2025Boost Price Target$44.39$41.00Hold$00.0000.00% ROIA $382 trillion migration and the position no one is talking about (Ad)Trump just signed a law requiring America's entire $382 trillion financial system to migrate to a new money network by April 2027. BlackRock CEO Larry Fink already calls it 'the next major evolution in market infrastructure.' Our research has identified one small, overlooked position at the center of this policy-driven shift - already drawing quiet institutional buying from BNY Mellon, State Street, and JPMorgan. It currently trades for pennies relative to where institutional demand could push it. The Q3 2026 compliance deadline may be the last window before prices move.Click here to see the full research and the position nameCELCCelcuity7/1/2025Initiated Coverage$13.35$30.00Buy$000.0000.00% ROICBIOCrescent Biopharma6/25/2025Initiated Coverage$15.06$28.00Buy$00.0000.00% ROIINCYIncyte6/16/2025Upgrade$67.75$107.00Buy$000.0000.00% ROIMGNXMacroGenics5/14/2025Lower Price Target$1.53$5.00Hold$0.0000.00% ROIEXELExelixis5/14/2025Boost Price Target$43.58$38.00Hold$00.0000.00% ROIBOLTBolt Biotherapeutics5/13/2025Lower Price Target$7.00$20.00Hold$0.0000.00% ROINRIXNurix Therapeutics4/9/2025Lower Price Target$8.88$35.00Buy$00.0000.00% ROINKTXNkarta3/27/2025Lower Price Target$1.37$14.00Buy$0.0000.00% ROIBOLTBolt Biotherapeutics3/25/2025Lower Price Target$8.75$25.00Hold$0.0000.00% ROIVORVor Biopharma3/21/2025Lower Price Target$17.04$100.00Buy$00.0000.00% ROIABCLAbCellera Biologics2/28/2025Lower Price Target$2.93$10.00Buy$0.0000.00% ROIGERNGeron2/27/2025Lower Price Target$1.62$4.00Buy$0.0000.00% ROIINSMInsmed2/21/2025Lower Price Target$84.49$96.00Buy$000.0000.00% ROIEXELExelixis2/12/2025Boost Price Target$35.11$36.00Hold$00.0000.00% ROIINSMInsmed2/11/2025Boost Price Target$78.94$97.00Buy$000.0000.00% ROIINCYIncyte2/10/2025Boost Price Target$68.30$77.00Hold$000.0000.00% ROINRIXNurix Therapeutics1/29/2025Boost Price Target$19.56$36.00Buy$00.0000.00% ROI Stock Forecasts and Research Tools Today's Analyst Ratings U.S. Ratings U.K. Ratings Canadian Ratings All Upgrades All Downgrades All Initiations All Price Target Changes Top-Rated Stocks Top Rated Stocks Top-Rated Dividend Stocks Top-Rated Small-Cap Stocks Top-Rated Tech Stocks Most-Upgraded Stocks Most-Downgraded Stocks Lowest-Rated Stocks More Ratings Tools Stock Ratings by Issuer Top-Rated Analysts Top-Rated Brokerages Stock Ratings Screener Free Ratings Newsletter Price Forecasts for Popular Stocks Alphabet (Google) Stock ForecastAmazon Stock ForecastApple Stock ForecastMeta (Facebook) Stock ForecastMicrosoft Stock ForecastNetflix Stock ForecastNvidia Stock ForecastTesla Stock Forecast Top Stock Recommendations by BrokerageWall Street ZenCitigroupUBS GroupBarclaysRoyal Bank Of CanadaMorgan StanleyWells Fargo & CompanyJPMorgan Chase & Co.Jefferies Financial GroupThe Goldman Sachs GroupTD CowenPiper SandlerDeutsche Bank AktiengesellschaftBMO Capital MarketsMizuho Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
